Pyxis Oncology reports FY2024 net loss $77.3M; MICVO 50% ORR in HNSCC; workforce cut 20%

Pyxis Oncology, Inc.

Full year 2024 net loss $77.3M ($1.32 per share) vs $73.8M ($1.85) in 2023; cash $128.4M into 2H26.
MICVO (formerly PYX-201) achieved 50% confirmed ORR by RECIST 1.1 in R/M HNSCC Phase 1; Fast Track designation received.
Initiated MICVO monotherapy expansion cohorts and a Phase 1/2 combo trial with Merck's KEYTRUDA; data expected 2H25/1H26.
Workforce reduced ~20% primarily in G&A and preclinical; CMO Ken Kobayashi steps down; CEO Lara Sullivan to also serve as CMO.
Suspended PYX-106 development; recorded $21M non-cash impairment on PYX-107 IPR&D intangible.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Lara S. Sullivan

Chief Medical Officer

PYXS · Pyxis Oncology, Inc.

Effective: 2025-03-18
Filed: March 18, 2025, 7:59 PM ET

Lara S. Sullivan, M.D., President and Chief Executive Officer will assume the role of Chief Medical Officer along with her current role as President and Chief Executive Officer.

Departed

Ken Kobayashi

Chief Medical Officer

PYXS · Pyxis Oncology, Inc.

Effective: 2025-03-18
Successor: Lara S. Sullivan
Filed: March 18, 2025, 7:59 PM ET

On March 18, 2025, the Company announced that Ken Kobayashi, M.D., F.A.C.P, is stepping down from his position as the Company's Chief Medical Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lara S. Sullivan changed role as Chief Medical Officer at Pyxis Oncology, Inc..

Action: assumed
Role: Chief Medical Officer

Exact text from the filing

Lara S. Sullivan, M.D., President and Chief Executive Officer will assume the role of Chief Medical Officer along with her current role as President and Chief Executive Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ken Kobayashi departed as Chief Medical Officer at Pyxis Oncology, Inc..

Action: stepping down
Role: Chief Medical Officer

Exact text from the filing

On March 18, 2025, the Company announced that Ken Kobayashi, M.D., F.A.C.P, is stepping down from his position as the Company's Chief Medical Officer.

View on SEC.gov

Pyxis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-040767

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.